Ionis Pharmaceuticals
Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical